← All Enliven Therapeutics, INC filings

Enliven Therapeutics, INC Form 4 insider transactions

NASDAQ
ELVN
Enliven Therapeutics, INC
Form 4: Enliven Therapeutics Director Rahul D. Ballal Executes Stock Option Exercises and Sales
Director Rahul D. Ballal of Enliven Therapeutics, Inc. reports exercising stock options and selling common stock under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
ELVN
Enliven Therapeutics, INC
Form 4: Enliven Therapeutics Director, Lori Anne Kunkel, Acquires Stock Options
Director Lori Anne Kunkel acquired stock options in Enliven Therapeutics, Inc. on April 8, 2024.
NASDAQ
ELVN
Enliven Therapeutics, INC
Form 4: Enliven Therapeutics COO Anish Patel Sells Shares Under 10b5-1 Trading Plan
Anish Patel, COO of Enliven Therapeutics, sold shares of common stock on April 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
ELVN
Enliven Therapeutics, INC
Form 4: Enliven Therapeutics Director Rahul D. Ballal Executes Option and Sells Shares Under 10b5-1 Plan
Director Rahul D. Ballal of Enliven Therapeutics exercised stock options and sold shares on April 4, 2024, under a pre-arranged 10b5-1 trading plan.
NASDAQ
ELVN
Enliven Therapeutics, INC
Form 4: Enliven Therapeutics Director Rahul Ballal Executes Option Exercises and Stock Sales Under 10b5-1 Plan
Director Rahul D. Ballal of Enliven Therapeutics, Inc. reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
ELVN
Enliven Therapeutics, INC
Form 4: Enliven Therapeutics Chief Scientific Officer Exercises Options and Sells Shares
Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, exercised stock options and sold shares of common stock on April 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
ELVN
Enliven Therapeutics, INC
Form 4: Enliven Therapeutics CFO Benjamin Hohl Exercises Options and Sells Shares
Benjamin Hohl, CFO of Enliven Therapeutics, executed option exercises and sales of common stock under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
ELVN
Enliven Therapeutics, INC
Form 4: Enliven Therapeutics CEO Samuel Kintz Executes Option and Sells Shares Under 10b5-1 Plan
Enliven Therapeutics' CEO, Samuel Kintz, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
ELVN
Enliven Therapeutics, INC
Form 4: Enliven Therapeutics Director Ballal Exercises Options and Sells Shares Under 10b5-1 Plan
Director Rahul D. Ballal exercised stock options and sold shares of Enliven Therapeutics, Inc. under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
ELVN
Enliven Therapeutics, INC
Form 4: Enliven Therapeutics Director Richard Heyman Sells Shares Under 10b5-1 Plan
Director Richard Heyman of Enliven Therapeutics sold 1,270 shares of common stock at a weighted average price of $14.5029, executed under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
ELVN
Enliven Therapeutics, INC
Form 4: Enliven Therapeutics COO Anish Patel Sells Shares Under 10b5-1 Trading Plan
Anish Patel, COO of Enliven Therapeutics, sold 4,875 shares of common stock on March 6, 2024, at a weighted average price of $15.6387, pursuant to a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
ELVN
Enliven Therapeutics, INC
Form 4: Enliven Therapeutics' Chief Scientific Officer Exercises Options and Sells Shares
Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, exercised stock options and sold shares on February 29, 2024, according to a Form 4 filing with the SEC.
NASDAQ
ELVN
Enliven Therapeutics, INC
Form 4: Enliven Therapeutics CFO Benjamin Hohl Executes Option Exercise and Stock Sale
Benjamin Hohl, CFO of Enliven Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
ELVN
Enliven Therapeutics, INC
Form 4: Enliven Therapeutics CEO Samuel Kintz Executes Option and Sells Shares Under 10b5-1 Plan
Enliven Therapeutics CEO Samuel Kintz exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.